Treating with ENJAYMO

Treating with ENJAYMO

ENJAYMO

Dosing Regimen

Starting ENJAYMO Calendar Icons Continuing ENJAYMO Calendar Icons
You will usually receive a starting dose of ENJAYMO, followed by a second dose of ENJAYMO 1 week later. Then 2 weeks after your second dose, you will receive an ENJAYMO infusion every 2 weeks.

ENJAYMO is an infusion that is given weekly for the first two weeks, with administration every two weeks thereafter.

ENJAYMO is given through a vein by intravenous (IV) infusion, usually over 1 to 2 hours.

After the first infusion, you should be monitored for allergic reactions for at least 2 hours. After future infusions, you should be monitored for at least 1 hour for allergic reactions.

Interruptions in ENJAYMO treatment:

  • If you have CAD and stop receiving ENJAYMO, your doctor should monitor you closely for return of your symptoms after you stop ENJAYMO.
  • Stopping ENJAYMO may cause a breakdown of your red blood cells due to CAD. Symptoms or problems that can happen due to red blood cell breakdown include: tiredness, shortness of breath, rapid heart rate, and/or blood in your urine or dark urine.
  • If you miss an ENJAYMO infusion, be sure to call your doctor right away.

ENJAYMO Infusion Process

The infusion process is an essential part of your treatment plan. This process can vary from patient to patient, so it's important to ask your healthcare provider what the process may look like for you.

Below is an example of what the infusion process could look like for you.

ENJAYMO Pre-Infusion IV Bag Icon

Pre-Infusion

  • Before starting treatment with ENJAYMO, it's important to talk to your doctor about your medical conditions and the medicines you take.
  • You need to receive vaccinations against infections caused by certain kinds of bacteria at least 2 weeks before your first dose of ENJAYMO. You may need to have additional vaccinations during treatment with ENJAYMO. Vaccinations may reduce the risk of these infections, but do not prevent all infections.
  • Make sure you call ahead to confirm your appointment.
  • Be sure to bring anything you may need during your treatment, things like a book, headphones, snacks, or bottled water.
ENJAYMO During Infusion IV Bag Icon

During Infusion

  • Your healthcare team will administer ENJAYMO through a vein by intravenous (IV) infusion.
  • The infusion time is 1 to 2 hours but may vary among patients.
  • Infusion-related reactions have been reported with ENJAYMO and may be serious or life-threatening. If you notice any of these reactions, talk to your doctor right away.
Clock Icon

Post-Infusion

  • Once the first infusion is complete, your healthcare team will monitor you for infusion-related and/or allergic reactions for at least 2 hours. For future infusions, you will be monitored for at least 1 hour.
  • If you miss an ENJAYMO infusion, be sure to call your doctor right away.
  • Before you leave, be sure to schedule your follow-up appointment.

ENJAYMO
Infusion Locations

ENJAYMO can be infused at:

Infusion Center Icon
An Infusion
Center
Doctor's Office Icon
Your Doctor's
Office
In-Home Infusion Icon
Your Home

To find out which option is suitable for you, speak with your doctor. Your infusion location options may depend on your health insurance coverage.

Clipboard Checklist Icon

Get Prepared for Your Next Visit

Use our Doctor Discussion Guide to have a productive conversation with your doctor or healthcare team to see if ENJAYMO is right for you.

Stay Connected Icon Sign Up to
Stay Informed

Whether you're taking ENJAYMO or interested in learning more, sign up to receive additional information, resources, and helpful tools to support you on your journey with Cold Agglutinin Disease.

Sign Up Now
×
INDICATION

ENJAYMO is a prescription medicine used to treat the breakdown of red blood cells (hemolysis) in adults with Cold Agglutinin Disease (CAD). It is not known if ENJAYMO is safe and effective in children.

IMPORTANT SAFETY INFORMATION AND INDICATION
+
INDICATION

ENJAYMO is a prescription medicine used to decrease the need for red blood cell transfusion due to the breakdown of red blood cells (hemolysis) in adults with cold agglutinin disease (CAD).

It is not known if ENJAYMO is safe and effective in children.

IMPORTANT SAFETY INFORMATION

Do not receive ENJAYMO if you are allergic to sutimlimab-jome or any of the ingredients in ENJAYMO.

ENJAYMO can cause serious side effects, including:

  • Serious Infections: ENJAYMO is a prescription medicine that affects a part of your immune system. ENJAYMO can lower the ability of your immune system to fight infections. People who take ENJAYMO may have an increased risk of getting infections caused by certain kinds of bacteria such as Neisseria meningitides, Streptococcus pneumoniae, and Haemophilus influenzae. These infections may be serious or life-threatening. Some infections may quickly become life-threatening or cause death if not recognized and treated early.
    • You need to receive vaccinations against infections caused by certain kinds of bacteria at least 2 weeks before your first dose of ENJAYMO. You may need to have additional vaccinations during treatment
    • If your healthcare provider decides that urgent treatment with ENJAYMO is needed, you should receive vaccinations as soon as possible.
    • Vaccinations may reduce the risk of these infections, but do not prevent all infections. Call your healthcare provider or get medical help right away if you get any new signs and symptoms of an infection, including:

      • fever
      • severe headache with stiff neck or back
      • pain during urination or urinating more often than usual
      • cough or difficulty breathing
      • flu-like symptoms
      • pain, redness or swelling of the skin
  • Infusion-related reactions: Treatment with ENJAYMO may cause infusion-related reactions, including allergic reactions that may be serious or life-threatening. Your healthcare provider may slow down or stop your ENJAYMO infusion if you have an infusion-related reaction, and will treat your symptoms if needed. Tell your healthcare provider right away if you develop symptoms during your ENJAYMO infusion that may mean you are having an infusion-related reaction, including
    • shortness of breath
    • rapid heartbeat
    • nausea
    • flushing
    • headache
  • Risk of autoimmune disease: ENJAYMO may increase your risk for developing an autoimmune disease such as systemic lupus erythematosus (SLE). Tell your healthcare provider and get medical help if you develop any symptoms of SLE, including:
    • joint pain or swelling
    • rash on the cheeks and nose
    • unexplained fever
  • If you have CAD and you stop receiving ENJAYMO, your healthcare provider should monitor you closely for return of your symptoms after you stop ENJAYMO. Stopping ENJAYMO may cause the breakdown of your red blood cells due to CAD to return. Symptoms or problems that can happen due to red blood cell breakdown include:
    • tiredness
    • shortness of breath
    • rapid heart rate
    • blood in your urine or dark urine

The most common side effects of ENJAYMO include:

  • respiratory tract infection
  • viral infection
  • diarrhea
  • indigestion
  • cough
  • joint pain
  • joint inflammation (arthritis)
  • Arthralgia
  • swelling of the lower legs, ankles, and feet

These are not all the possible side effects of ENJAYMO. Call your doctor for medical advice about side effects.

Before receiving ENJAYMO, tell your healthcare provider about all of your medical conditions, including if you:

  • have a fever or infection, including a history of human immunodeficiency virus (HIV), hepatitis B, or hepatitis C.
  • have an autoimmune disease such as systemic lupus erythematosus (SLE), also known as lupus.
  • are pregnant or plan to become pregnant. It is not known if ENJAYMO will harm your unborn baby.
  • are breastfeeding or plan to breastfeed. It is not known if ENJAYMO passes into your breast milk.

Tell your healthcare provider about all the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements.

Please see Full Prescribing Information, including Medication Guide.

×
INDICATION

ENJAYMO is a prescription medicine used to decrease the need for red blood cell transfusion due to the breakdown of red blood cells (hemolysis) in adults with cold agglutinin disease (CAD).

It is not known if ENJAYMO is safe and effective in children.

IMPORTANT SAFETY INFORMATION AND INDICATION
+
INDICATION

ENJAYMO is a prescription medicine used to decrease the need for red blood cell transfusion due to the breakdown of red blood cells (hemolysis) in adults with cold agglutinin disease (CAD).

It is not known if ENJAYMO is safe and effective in children.

IMPORTANT SAFETY INFORMATION

Do not receive ENJAYMO if you are allergic to sutimlimab-jome or any of the ingredients in ENJAYMO.

ENJAYMO can cause serious side effects, including:

  • Serious Infections: ENJAYMO is a prescription medicine that affects a part of your immune system. ENJAYMO can lower the ability of your immune system to fight infections. People who take ENJAYMO may have an increased risk of getting infections caused by certain kinds of bacteria such as Neisseria meningitides, Streptococcus pneumoniae, and Haemophilus influenzae. These infections may be serious or life-threatening. Some infections may quickly become life-threatening or cause death if not recognized and treated early.
    • You need to receive vaccinations against infections caused by certain kinds of bacteria at least 2 weeks before your first dose of ENJAYMO. You may need to have additional vaccinations during treatment
    • If your healthcare provider decides that urgent treatment with ENJAYMO is needed, you should receive vaccinations as soon as possible.
    • Vaccinations may reduce the risk of these infections, but do not prevent all infections. Call your healthcare provider or get medical help right away if you get any new signs and symptoms of an infection, including:

      • fever
      • severe headache with stiff
        neck or back
      • pain during urination or urinating
        more often than usual
      • cough or difficulty breathing
      • flu-like symptoms
      • pain, redness or
        swelling of the skin
  • Infusion-related reactions: Treatment with ENJAYMO may cause infusion-related reactions, including allergic reactions that may be serious or life-threatening. Your healthcare provider may slow down or stop your ENJAYMO infusion if you have an infusion-related reaction, and will treat your symptoms if needed. Tell your healthcare provider right away if you develop symptoms during your ENJAYMO infusion that may mean you are having an infusion-related reaction, including:
    • shortness of breath
    • rapid heartbeat
    • nausea
    • flushing
    • headache
  • Risk of autoimmune disease: ENJAYMO may increase your risk for developing an autoimmune disease such as systemic lupus erythematosus (SLE). Tell your healthcare provider and get medical help if you develop any symptoms of SLE, including:
    • joint pain or swelling
    • rash on the cheeks and nose
    • unexplained fever
  • If you have CAD and you stop receiving ENJAYMO, your healthcare provider should monitor you closely for return of your symptoms after you stop ENJAYMO. Stopping ENJAYMO may cause the breakdown of your red blood cells due to CAD to return. Symptoms or problems that can happen due to red blood cell breakdown include:
    • tiredness
    • shortness of breath
    • rapid heart rate
    • blood in your urine or dark urine

The most common side effects of ENJAYMO include:

  • respiratory tract infection
  • viral infection
  • diarrhea
  • indigestion
  • cough
  • joint pain
  • joint inflammation (arthritis)
  • swelling of the lower legs, ankles, and feet

These are not all the possible side effects of ENJAYMO. Call your doctor for medical advice about side effects.

Before receiving ENJAYMO, tell your healthcare provider about all of your medical conditions, including if you:

  • have a fever or infection, including a history of human immunodeficiency virus (HIV), hepatitis B, or hepatitis C.
  • have an autoimmune disease such as systemic lupus erythematosus (SLE), also known as lupus.
  • are pregnant or plan to become pregnant. It is not known if ENJAYMO will harm your unborn baby.
  • are breastfeeding or plan to breastfeed. It is not known if ENJAYMO passes into your breast milk.

Tell your healthcare provider about all the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements.

Please see Full Prescribing Information, including Medication Guide.